IDEAYA Biosciences Inc., a precision medicine oncology company, has announced that data from its Phase 2 clinical trial of neoadjuvant darovasertib in primary uveal melanoma will be presented at the 2025 European Society of Medical Oncology (ESMO) meeting, scheduled for October 17-21 in Berlin, Germany. The presentation will cover preliminary results from over 90 patients across both plaque brachytherapy and enucleation-eligible cohorts. Darovasertib has received U.S. FDA Breakthrough Therapy Designation for this indication, and the company has commenced a global Phase 3 neoadjuvant registrational trial in primary uveal melanoma, known as OptimUM-10, in the third quarter of 2025. Dr. Marcus Butler from the Princess Margaret Cancer Center at the University of Toronto will present the findings. Further details from the abstract will be disclosed at a later date.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.